Buprenorphine Market size was valued at USD 5.44 billion in 2023 and is expected to exceed USD 31.27 billion by 2036, registering over 14.4% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of buprenorphine is assessed at USD 6.07 billion.
The growth of the market can be attributed to the growing prevalence of chronic pain disorders, increasing occurrence of cancer. According to the World Health Organization (WHO), cancer is the leading cause of deaths worldwide, accounting to about 10 million deaths in the year 2020. In addition to these, escalating government investments in healthcare in developed nations and rising usage of buprenorphine patches as an effective treatment mode is also anticipated to drive market growth in the coming years. Furthermore, the growing dependency on painkillers has led to opioid addiction to many people around the world, which in turn is projected to provide lucrative opportunities to significantly raise the demand for buprenorphine in the near future.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
14.4% |
|
Base Year Market Size (2023) |
USD 5.44 billion |
|
Forecast Year Market Size (2036) |
USD 31.27 billion |
|
Regional Scope |
|
The market is segmented by route of administration into sublingual, transdermal, and buccal, out of which, the sublingual segment is anticipated to hold the largest share in the buprenorphine market on account of the increasing availability of buprenorphine drugs in several dosages in the sublingual form. Along with this, rapid drug absorption, first-pass metabolism and quick onset of action of sublingual route of administration are also predicted to boost the growth of the market segment in the forecast period. Additionally, the segment for buccal dosage is expected to witness notable growth in the future, which can be credited to the increasing number of people opting for oral drugs as compared to injection-based drugs.
Our in-depth analysis of the global market includes the following segments
|
By Route Of Administration
|
|
|
By Distribution Channel |
|
North America Market Statistics
On the basis of geographical analysis, the market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America is set to account for largest revenue share by 2036, on the back of strong presence of market players and growing percentage of the population suffering from opioid dependency in the region. As per the data by National Institute of Drug Abuse, 21 to 29 percent of patients misuse the opioids prescribed for chronic pain. Amongst these, 8-12% people develop an opioid use disorder. Apart from these, high number of cases of abuse related to drugs such as heroin and cocaine is also anticipated to drive the region’s market growth in the forthcoming years.
Europe Market Analysis
Europe is also expected to acquire a notable share in the market owing to the large number of new medical product launches in the region. Moreover, the market in Asia Pacific is projected to witness noteworthy growth during the forecast period ascribing to the rising patient pool and growing awareness about the health benefits of buprenorphine in the region.
· June 2021: Purdue Pharma LP announced that FDA accepted and filing of the abbreviated new drug application for vial dosage form of nalmefene hydrochloride injection, which is designed to treat opioid overdose.
· May 2020: Hikma Pharmaceuticals PLC launched Buprenorphine Hydrochloride Injection, 0.3mg/mL in the United States through its American affiliate
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?